Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVS SR in Peri- and Postmenopausal Women with MDD
NCT01121484Phase 4Completed
- Sponsor
- Pfizer
- Start
- Jun 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of desvenlafaxine in major depressive disorder (MDD) (2 arms), sponsored by Pfizer. Primary endpoint: Hamilton Depression Scale at 8 weeks. Started Jun 2010; status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01121484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01121484.